# rs4784227 and Breast cancer (16q12)

Configuration `single`, named mode, seed 0. Models: generator openai/gpt-6-luna, critic openai/gpt-6-luna, summariser openai/gpt-6-luna. Cost $0.00 over 1 model calls; 60 s.

Variant `chr16:52565276:C>T` (germline); expression context: DepMap:ACH-000019 (MCF7).

## Ranked chains

### 1. H1: T strengthens FOXA1-dependent TOX3 enhancer activity (p = 0.50)

TF FOXA1 (QBiC-SELEX coverage own_model), alt allele binds more; element The variant lies in a candidate cis-regulatory element that enhances TOX3 expression.; gene TOX3; cell type Luminal breast cancer cells, including MCF7..

| Step | Claim | Status | Evidence |
| --- | --- | --- | --- |
| binding | FOXA1 is the leading candidate based on the reported biology of this breast-cancer locus; this hypothesis is that alt T binds FOXA1 more strongly. No QBiC-SELEX result is supplied here to establish the allelic direction. | missing | none |
| element | The variant-containing sequence acts as a FOXA1-responsive enhancer. | missing | none |
| gene | The enhancer increases TOX3 transcription. | missing | none |
| cell_type | The effect occurs in luminal breast cells where FOXA1 is relevant, such as MCF7. | missing | none |
| phenotype | Increased TOX3 expression contributes to increased breast-cancer susceptibility. | missing | none |

Predictions: The T allele will show greater FOXA1 occupancy than C at the endogenous site.; The T-containing element will drive more enhancer activity and higher TOX3 expression than the C-containing element in a relevant breast-cell context.

Falsified if: Allele-resolved occupancy shows no T-biased FOXA1 binding, or shows stronger binding to C.; The T allele does not increase enhancer output or TOX3 expression in an appropriate breast-cell context.

### 2. H0: No TF-mediated effect of this variant (p = 0.25)

Null chain: no TF-mediated effect of this variant.

Predictions: The variant will show no reproducible allele-dependent TF occupancy or regulatory output in an appropriate breast-cell context.; Any association may reflect linkage to another causal variant or another non-TF-mediated explanation.

Falsified if: Endogenous allele replacement produces a reproducible TF-dependent change in regulatory output and a downstream gene-expression effect.

### 3. H2: T strengthens FOXA1 binding but reduces TOX3 enhancer output (p = 0.18)

TF FOXA1 (QBiC-SELEX coverage own_model), alt allele binds more; element The variant-containing sequence is a FOXA1-responsive regulatory element whose output is repressive in this context.; gene TOX3; cell type Luminal breast cancer cells, including MCF7..

| Step | Claim | Status | Evidence |
| --- | --- | --- | --- |
| binding | FOXA1 is the candidate TF; this alternative also hypothesizes stronger binding to alt T, but no QBiC-SELEX result is supplied to establish that direction. | missing | none |
| element | The variant-containing element recruits FOXA1 in a context where FOXA1 binding reduces its enhancer output. | missing | none |
| gene | Reduced element output lowers TOX3 expression. | missing | none |
| cell_type | The regulatory effect occurs in luminal breast cells, including MCF7. | missing | none |
| phenotype | Reduced TOX3 expression increases breast-cancer susceptibility. | missing | none |

Predictions: The T allele will show greater FOXA1 occupancy than C.; Despite greater occupancy, the T-containing element will produce less reporter activity and lower TOX3 expression than the C-containing element.

Falsified if: The T allele does not show greater FOXA1 occupancy.; The T-containing element increases rather than reduces regulatory output and TOX3 expression.

### 4. H3: A different luminal TF mediates the allele effect on TOX3 (p = 0.07)

TF GATA3 (QBiC-SELEX coverage own_model), ref allele binds more; element The variant-containing sequence is a GATA3-responsive enhancer of TOX3.; gene TOX3; cell type Luminal breast cells expressing GATA3..

| Step | Claim | Status | Evidence |
| --- | --- | --- | --- |
| binding | GATA3 is an alternative luminal TF candidate; this hypothesis is that ref C binds it more strongly. No QBiC-SELEX result or allele-specific occupancy evidence is supplied for GATA3. | missing | none |
| element | The variant-containing sequence acts as a GATA3-responsive enhancer. | missing | none |
| gene | GATA3-dependent activity of the element increases TOX3 expression. | missing | none |
| cell_type | The effect occurs in GATA3-expressing luminal breast cells. | missing | none |
| phenotype | The resulting change in TOX3 expression contributes to breast-cancer susceptibility. | missing | none |

Predictions: The C allele will show greater GATA3 occupancy than T.; Changing GATA3 abundance or activity will alter the allele-dependent effect on TOX3.

Falsified if: GATA3 does not occupy the variant-containing element in relevant cells.; The allelic effect persists unchanged when GATA3 activity is reduced.

## Prediction matrix

| Test | Cost | Separates top two | H1 | H0 | H2 | H3 |
| --- | --- | --- | --- | --- | --- | --- |
| Paired C-versus-T enhancer reporter assay in MCF7 cells, with TOX3 enhancer output measured. | low | yes | T gives higher reporter activity than C. | No reproducible difference between C and T. | T gives lower reporter activity than C. | C is predicted to give higher activity; the effect should depend on GATA3. |
| Allele-resolved FOXA1 occupancy at the endogenous variant in heterozygous MCF7 cells. | medium | no | Greater FOXA1 occupancy on T. | No variant-linked allele bias in occupancy. | Greater FOXA1 occupancy on T. | FOXA1 occupancy need not be allele-biased. |
| Measure allele-specific TOX3 expression after endogenous C-to-T or T-to-C editing in a relevant breast-cell model. | high | yes | T increases TOX3 expression. | Editing the variant alone produces no reproducible TOX3 expression change. | T decreases TOX3 expression. | The expression effect depends on GATA3 and favors the C allele. |

## Next experiment

Run the low-cost paired C-versus-T enhancer reporter assay in MCF7 cells. It directly distinguishes the top two hypotheses by testing whether the T allele raises or lowers regulatory output; a positive result would still need endogenous validation.

## Flags

- none

## Evidence
